2 terminated, 2 unknown, 1 active not recruiting, 1 completed. 7 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 2, Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 2 | 5 | Terminated 2, Unknown 2, Active not recruiting 1 |
Follow Eye Abnormalities: new trials by email Literature Review of Eye Abnormalities trials Research Report on Eye Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
| Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle - Pediatric Glaucoma, Elevated IOP in Pediatric Patients | Phase 3 | Completed | Alcon Research | 184 | 2012-09-01 | 2015-07-23 |
| Prosthetic Motility and Complications in Pegged Versus Unpegged Hydroxyapatite Orbital Implants orbital implant - Anophthalmos, Orbital Implants | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 50 | 2005-11-01 | 2010-05-12 |
Eye Diseases (5) · Retinal Diseases (5) · Vision Disorders (5) · Eye Diseases, Hereditary (4) · Blindness (3) · Leber Congenital Amaurosis (3) · Leber Congenital Amaurosis 10 (3) · Meckel Syndrome, Type 4 (3) · Neurologic Manifestations (3) · Sensation Disorders (3) · Optic Atrophy, Hereditary, Leber (2) · Retinitis Pigmentosa (2) · Usher Syndromes (2) · Anophthalmos (1)
Congenital Abnormalities (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Nervous System Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (5) · Genetic Diseases, Inborn (4) · Abnormalities, Multiple (2) · Blindness (2) · Cranial Nerve Diseases (2) · Deaf-Blind Disorders (2) · Deafness (2) · Ear Diseases (2) · Eye Diseases (2) · Hearing Disorders (2)
Intravitreal Injections (2) · Ophthalmic Solutions (1) · Orbital Implants (1) · Timolol (1) · Travoprost (1) · salicylhydroxamic acid (1)
Laboratoires Thea (3) · ProQR Therapeutics (2) · Alcon Research (1) · Shahid Beheshti University of Medical Sciences (1)
United Kingdom (5) · Germany (4) · Netherlands (4) · United States (4) · Belgium (3) · Brazil (3) · Canada (3) · France (2) · Italy (2) · Australia (1) · Iran (1) · Spain (1)
Babak Babsharif, MD (1) · Subha Venkataraman, Clinical Project Lead (1)
2018 (1)